Antibacterial resistance and the success of tailored triple therapy in Helicobacter pylori strains isolated from Slovenian children

Tita Butenko, Samo Jeverica, Rok Orel, Matjaž Homan, Tita Butenko, Samo Jeverica, Rok Orel, Matjaž Homan

Abstract

Background: Primary Helicobacter pylori (H. pylori) infection occurs predominantly in childhood. Antimicrobial resistance is the leading cause for H. pylori eradication failure. The aims of this study were (i) to establish for the first time the antimicrobial resistance of H. pylori strains in infected Slovenian children not previously treated for H. pylori infection and (ii) to evaluate the effectiveness of tailored triple therapy, assuming that eradication rate with tailored triple therapy will be >90%.

Methods: Data on all treatment-naive children 1-18 years old and treated for H. pylori infection according to susceptibility testing were retrospectively analyzed. All relevant clinical information and demographical information were retrospectively collected from the hospital information systems and/or patients' medical documentation.

Results: The inclusion criteria were met by 107 children (64.5% girls) with a median age of 12.0 years (range 2.0-17.6 years). Primary antimicrobial resistance rates of H. pylori were 1.0% to amoxicillin (AMO), 23.4% to clarithromycin (CLA), 20.2% to metronidazole (MET), 2.8% to levofloxacin (LEV), and 0.0% to tetracycline (TET). Dual resistances were detected to CLA and MET in 11.5% (n=12) of strains, to CLA and LEV in 2.8% (n=3), and to MET and LEV in 2.9% (n=3). Results of treatment success were available for 71 patients (66.2% girls). Eradication of H. pylori was evaluated using the 13C-urea breath test, monoclonal stool antigen test or in some cases with repeated upper GI endoscopy with histology and cultivation/molecular tests. Eradication was achieved in 61 of 71 (85.9%) patients.

Conclusions: The primary resistance rates of H. pylori to CLA and MET in Slovenia are high. Our data strongly support the fact that in countries with high prevalence of resistant H. pylori strains susceptibility testing and tailored therapy is essential.

Keywords: children; eradication rate; infection with Helicobacter pylori; primary resistance.

© 2017 The Authors Helicobacter Published by John Wiley & Sons Ltd.

References

    1. Kindermann A, Lopes AI. Helicobacter pylori infection in paediatrics. Helicobacter. 2009;14(Suppl 1):52‐57.
    1. Pellicano R, Franceschi F, Saracco G, Fagoonee S, Roccarina D, Gasbarrini A. Helicobacters and extragastric diseases. Helicobacter. 2009;14(Suppl 1):58‐68.
    1. Koletzko S, Jones NL, Goodman KJ, et al. Evidence‐based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2011;53:230‐243.
    1. Bontems P, Kalach N, Oderda G, et al. Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2011;53:646‐650.
    1. Oderda G, Shcherbakov P, Bontems P, et al. Results from the paediatric European register for treatment of Helicobacter pylori (PERTH). European Pediatric Task Force on Helicobacter pylori . Helicobacter. 2007;12:150‐156.
    1. Koletzko S, Richy F, Bontems P, et al. Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe. Gut. 2006;55:1711‐1716.
    1. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence‐based medicine rather than medicine‐based evidence. Clin Gastroenterol Hepatol. 2014;12:177‐186.
    1. Oleastro M, Cabral J, Ramalho PM, et al. Primary antibiotic resistance of Helicobacter pylori strains isolated from Portuguese children: a prospective multicentre study over a 10 year period. J Antimicrob Chemother. 2011;66:2308‐2311.
    1. Vécsei A, Kipet A, Innerhofer A, et al. Time trends of Helicobacter pylori resistance to antibiotics in children living in Vienna, Austria. Helicobacter. 2010;15:214‐220.
    1. Boyanova L, Nikolov R, Lazarova E, et al. Antibacterial resistance in Helicobacter pylori strains isolated from Bulgarian children and adult patients over 9 years. J Med Microbiol. 2006;55(Pt 1):65‐68.
    1. Janssen MJ, Hendrikse L, de Boer SY, et al. Helicobacter pylori antibiotic resistance in a Dutch region: trends over time. Neth J Med. 2006;64:191‐195.
    1. Schwarzer A, Urruzuno P, Iwańczak B, et al. New effective treatment regimen for children infected with a double‐resistant Helicobacter pylori strain. J Pediatr Gastroenterol Nutr. 2011;52:424‐428.
    1. Fürst J, Čižman M, Mrak J, et al. The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: findings and implications. Expert Rev Anti Infect Ther. 2015;13:279‐289.
    1. Iwańczak F, Iwańczak B. Treatment of Helicobacter pylori infection in the aspect of increasing antibiotic resistance. Adv Clin Exp Med. 2012;21:671‐680.
    1. Hojsak I, Kos T, Dumančić J, et al. Antibiotic resistance of Helicobacter pylori in pediatric patients—10 years’ experience. Eur J Pediatr. 2012;171:1325‐1330.
    1. Agudo S, Alarcón T, Cibrelus L, Urruzuno P, Martínez MJ, López‐Brea M. High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children. Rev Esp Quimioter. 2009;22:88‐92.
    1. Arenz T, Antos D, Rüssmann H, et al. Esomeprazole‐based 1‐week triple therapy directed by susceptibility testing for eradication of Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr. 2006;43:180‐184.
    1. Kato S, Konno M, Maisawa S, et al. Results of triple eradication therapy in Japanese children: a retrospective multicenter study. J Gastroenterol. 2004;39:838‐843.
    1. Street ME, Caruana P, Caffarelli C, et al. . Antibiotic resistance and antibiotic sensitivity based treatment in Helicobacter pylori infection: advantages and outcome. Arch Dis Child. 2001;84:419‐422.
    1. Wu TS, Hu HM, Kuo FC, Kuo CH. Eradication of Helicobacter pylori infection. Kaohsiung J Med Sci. 2014;30:167‐172.
    1. Gościniak G, Iwańczak B, Przondo‐Mordarska A, Grabińska J, Iwańczak F. High level of resistance to metronidazole and clarithromycin in Helicobacter pylori isolated from pediatric patients in Poland (1997–2001). Folia Microbiol (Praha). 2004;49:133‐136.
    1. Miyaji H, Azuma T, Ito S, et al. Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. Aliment Pharmacol Ther. 1997;11:1131‐1136.
    1. Yakoob J, Fan XG, Hu GL, et al. Polycolonization of Helicobacter pylori among Chinese subjects. Clin Microbiol Infect. 2001;7:187‐192.
    1. Homan M, Luzar B, Kocjan BJ, et al. Prevalence and clinical relevance of cagA, vacA, and iceA genotypes of Helicobacter pylori isolated from Slovenian children. J Pediatr Gastroenterol Nutr. 2009;49:289‐296.
    1. Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol. 2003;17(Suppl B):36B‐40B.
    1. Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013;12:CD008337.
    1. Oderda G, Rapa A, Bona G. A systematic review of Helicobacter pylori eradication treatment schedules in children. Aliment Pharmacol Ther. 2000;14(Suppl 3):59‐66.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner